The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease

Gastrointestinal Endoscopy Clinics of North America

Volumn 24, Issue 3, 2014, Pages 353-365

  Chapman, Christopher G ^a   Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Inflammatory bowel disease; Medical therapy; Surveillance endoscopy

Indexed keywords

MERCAPTOPURINE; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; URSODEOXYCHOLIC ACID; AZATHIOPRINE; CHOLAGOGUE; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; DISEASE CONTROL; DISEASE SEVERITY; DISEASE SURVEILLANCE; DISEASES; DYSPLASIA; ENDOSCOPIST; ENDOSCOPY; HEALING; HISTOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; MUCOSAL HEALING; NONHUMAN; PATHOLOGIST; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; COMPLICATION; EARLY DIAGNOSIS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; PROCEDURES;

6-MERCAPTOPURINE; ADENOCARCINOMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; CHOLAGOGUES AND CHOLERETICS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MESALAMINE; TUMOR NECROSIS FACTOR-ALPHA; URSODEOXYCHOLIC ACID;

EID: 84903442450     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2014.03.008     Document Type: Review

References (48)

1. Kornbluth A., Sachar D.B., Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105(3):501-523. [quiz: 524].
2. Andersen N.N., Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased?. World J Gastroenterol 2013, 19(43):7561-7568.
3. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140(6):1807-1816.
4. Sebastian S., Hernández V., Myrelid P., et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). JCrohns Colitis 2014, 8(1):5-18.
5. Rubin D.T., Huo D., Kinnucan J.A., et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol 2013, 11(12):1601-1608.e1-4.
6. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53(12):1813-1816.
7. Rubin D.T. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing?. Clin Gastroenterol Hepatol 2011, 9(6):456-457.
8. Baars J.E., Nuij V.J., Oldenburg B., et al. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2012, 18(9):1634-1640.
9. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98(4):811-818.
10. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7(1):15-29.
11. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9(6):483-489.e3.
12. Froslie K.F., Jahnsen J., Moum B.A., et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133(2):412-422.
13. Rubin D.T., Koduru P., Surma B., et al. Frequency of Sub-Clinical Disease Activity in Ulcerative Colitis Patients [abstract]. Chicago: DDW 2011.
14. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69(4):631-637.
15. Leighton J.A., Shen B., Baron T.H., et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006, 63(4):558-565.
16. Itzkowitz S.H., Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004, 126(6):1634-1648.
17. Eaden J.A., Ward B.A., Mayberry J.F. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000, 51(2):123-128.
18. Rutter M.D., Saunders B.P., Wilkinson K.H., et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004, 60(3):334-339.
19. Rubin D.T., Rothe J.A., Hetzel J.T., et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. Gastrointest Endosc 2007, 65(7):998-1004.
20. Feldman M., Friedman L., Brandt L. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management 2010, Saunders/Elsevier, Philadelphia. 9th edition.
21. Actis G.C., Tarallo S., Rosina F. Cutting edge: chemoprevention of colorectal neoplasia in inflammatory bowel disease. Inflamm Allergy Drug Targets 2013, 12(1):1-7.
22. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126(2):451-459.
23. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133(4):1099-1105. [quiz: 1340-1].
24. Lyakhovich A., Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010, 31(2):202-209.
25. Rubin D.T., Cruz-Correa M.R., Gasche C., et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008, 14(2):265-274.
26. Subramanian V., Logan R.F. Chemoprevention of colorectal cancer in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2011, 25(4-5):593-606.
27. Pinczowski D., Ekbom A., Baron J., et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107(1):117-120.
28. Velayos F.S., Terdiman J.P., Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005, 100(6):1345-1353.
29. Baars J.E., Looman C.W., Steyerberg E.W., et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011, 106(2):319-328.
30. Bernstein C.N., Nugent Z., Blanchard J.F. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011, 106(4):731-736.
31. Jess T., Loftus E.V., Velayos F.S., et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007, 102(4):829-836.
32. Terdiman J.P., Steinbuch M., Blumentals W.A., et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(4):367-371.
33. van Schaik F.D., van Oijen M.G., Smeets H.M., et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012, 61(2):235-240.
34. Nguyen G.C., Gulamhusein A., Bernstein C.N., et al. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012, 107:1298-1304.
35. Farraye F.A., Odze R.D., Eaden J., et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138(2):746-774. 774.e1-4. [quiz: e12-3].
36. Farraye F.A., Odze R.D., Eaden J., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138(2):738-745.
37. Pasternak B., Svanström H., Schmiegelow K., et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013, 177(11):1296-1305.
38. Beaugerie L., Svrcek M., Seksik P., et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013, 145(1):166-175.e8.
39. Gong J., Zhu L., Guo Z., et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One 2013, 8(11):e81487.
40. Popivanova B.K., Kitamura K., Wu Y., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. JClin Invest 2008, 118(2):560-570.
41. Pardi D.S., Loftus E.V., Kremers W.K., et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124(4):889-893.
42. Eaton J.E., Silveira M.G., Pardi D.S., et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011, 106(9):1638-1645.
43. Vieira A., Fang C.B., Rolim E.G., et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009, 2:221.
44. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med 2005, 353(23):2462-2476.
45. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146(1):85-95. [quiz: e14-5].
46. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142(2):257-265.e1-3.
47. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63(3):433-442. [quiz: 464].
48. Rutgeerts P., van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142(5):1102-1111.e2.